Pharmacological profiles and clinical effects of blonanserin (Lonasen®) on schizophrenia

Folia Pharmacologica Japonica

Volumn 132, Issue 6, 2008, Pages 351-360

  Ishibashi, Tadashi ^a   Nishikawa, Hiroyuki ^a   Une, Teruaki ^a   Nakamura, Hiroshi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; ARIPIPRAZOLE; BLONANSERIN; HALOPERIDOL; HISTAMINE H1 RECEPTOR; MUSCARINIC M1 RECEPTOR; OLANZAPINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; ANTIDEPRESSANT AGENT; DOPAMINE 2 RECEPTOR; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE;

DRUG EFFICACY; DRUG STRUCTURE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; POSITIVE AND NEGATIVE SYNDROME SCALE; REVIEW; SCHIZOPHRENIA; ANIMAL; COGNITIVE DEFECT; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG DEVELOPMENT; DRUG TOXICITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG DISCOVERY; DRUG TOXICITY; HUMANS; PIPERAZINES; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 59449092585     PISSN: 00155691     EISSN: 13478397     Source Type: Journal    
DOI: 10.1254/fpj.132.351     Document Type: Review

References (30)

1. Japanese source
2. Castelão JF, et al. Schizophr Res. 19892:411-415.
3. Ceulemans DLS, et al. Psychopharmacology. 1985;85:329-332.
4. Japanese source
5. Japanese source
6. Japanese source
7. Japanese source
8. Meltzer HY, et al. J Pharmacol Exp Ther. 1989;251:238-246.
9. Cook L, et al. Neuropsychopharmacology. Vol 2. Elsevier Publ; 1961. p. 77-92.
10. Clody DE, et al. Predictability in Psychopharmacology: Preclinical and Clinical Correlations. Raven Press; 1975. p. 213-224.
11. Kuribara H, et al. Pharmacol Biochem Behav. 1981;14:181-192.
12. Japanese source
13. Noda Y, et al. Br J Pharmacol. 1996;117:1579-1585.
14. Noda Y, et al. Br J Pharmacol. 1995;116:2531-2537.
15. Nagai T, et al. Neuroreport. 2003;14:269-272.
16. Swerdlow NR, et al. Schizophr Bull. 1998;24:285-301.
17. VanRossum JM, et al. Modern Problem of Pharmacology. Vol 5. Karger; 1970. p. 23-70.
18. Janssen PAJ, et al. Current Developments in Psychopharmacology. Vol 2. Spectrum Publ Inc; 1975. p. 165-184.
19. Boissier JR, et al. Thérapie. 1960;15:1170-1174.
20. Clark D, et al. Synapse. 1987;1:347-388.
21. See RE, et al. Eur J Pharmacol. 1990;181:175-186.
22. Japanese source
23. Japanese source
24. Japanese source
25. Japanese source
26. Heinrichs RW, et al. Neuropsychology. 1998;12:426-445.
27. Japanese source
28. Japanese source
29. Japanese source
30. Japanese source